Use of Immune Suppressive Domains as Medicaments

Abstract

The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.

1 . Pharmaceutical product comprising an immune suppressive domain from a virus fusion protein as an active substance, wherein said immune suppressive domain is from a virus of the Orthomyxoviridae family. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein said pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, preservative, buffer, and/or surfactant. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein said immune suppressive domain is from a virus of the Influenza virus A genus. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein said immune suppressive domain comprises SEQ ID NO: 4 and/or SEQ ID NO: 287. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein said immune suppressive domain is connected to at least one additional immune suppressive domain to form a dimer. 
     
     
         6 . The pharmaceutical composition according to  claim 5 , wherein said dimer is a homodimer and comprises at least two immune suppressive domains with SEQ ID NO. 4, wherein said immune suppressive domains are cross-linked by a disulfide bond at the N-terminal or the C-terminal. 
     
     
         7 . A pharmaceutical composition comprising an immunosuppressive polypeptide that is a dimer formed by two peptides comprising SEQ ID NO: 4 as an active substance subject to at least one of the following provisos:
 (i) said pharmaceutical composition is a parenteral, subcutaneous or oral formulation;   (ii) said pharmaceutical composition is an injection liquid or infusion liquid;   (iii) said pharmaceutical composition comprises a pharmaceutically acceptable carrier selected from solid, semisolid and liquid;   (iv) said pharmaceutical composition is a suspension, solution, emulsion, gel, cream, or powder;   (v) said pharmaceutical composition comprises 0.5-25% by weight of said peptides in solution; or   (vi) said two peptides comprise SEQ ID NO: 4 and an additional cysteine at the C-terminal or N-terminal end of SEQ ID NO: 4, wherein said cysteine residues crosslink the two peptides via a disulfide bond.   
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein said pharmaceutical composition is selected from a parenteral composition, a subcutaneous formulation, and an oral composition. 
     
     
         9 . The pharmaceutical composition according to  claim 7 , wherein said pharmaceutical composition is suitable for IV, oral, parenteral, intraperitoneal, subcutaneous or intramuscular administration. 
     
     
         10 . A pharmaceutical composition according to  claim 7 , wherein said pharmaceutical composition is packaged in unit-dose or multi-dose sealed containers, and/or packaged in ampoules and/or vials. 
     
     
         11 . The pharmaceutical composition according to  claim 7 , wherein said pharmaceutical composition is a vaccine. 
     
     
         12 . The pharmaceutical composition according to  claim 7  obtainable by freeze-drying or which is suitable to be stored in a freeze-dried (lyophilized) condition. 
     
     
         13 . The pharmaceutical composition according to  claim 7  comprising a pharmaceutically acceptable carrier, preservative, buffer, and/or surfactant. 
     
     
         14 . A pharmaceutical composition according to  claim 7 , wherein one or more amino acid residues in said polypeptide are modified by in vitro or in vivo chemical derivatization, wherein said chemical derivatization is selected from acetylation, carboxylation, glycosylation and phosphorylation, or wherein said polypeptide comprises blocking groups and wherein said blocking groups are either coupled to the N-terminus or used in place of the N-terminal amino acid residue of said polypeptide and/or coupled to the C-terminus or used in place of the C-terminal amino acid residue of said polypeptide. 
     
     
         15 . The pharmaceutical composition according to  claim 7 , wherein the two peptides comprise a cysteine residue at a C-terminal end of SEQ ID NO. 4. 
     
     
         16 . The pharmaceutical composition according to  claim 7 , wherein each of the two peptides consists of SEQ ID NO. 287. 
     
     
         17 . The pharmaceutical composition according to  claim 7 , wherein said immune suppressive domains are cross-linked by a disulfide bond at the N-terminal or the C-terminal. 
     
     
         18 . The pharmaceutical composition according to  claim 7 , wherein said dimer is a homodimer. 
     
     
         19 . The pharmaceutical composition of  claim 7 , wherein said composition contains from 0.5 to 25% by weight of the active substance in solution. 
     
     
         20 . A peptide comprising SEQ ID NO. 287.